Lonza Group AG

Swiss Stock Exchange:LONN.SW

Sector

🏥 Health Care

Industries

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 49.39 B

Share Price

USD 684.56

Avg Daily Volume

174,942

Change (1 day)

0.23%

Change (1 year)

27.07%

Change (YTD)

15.54%

Lonza Group AG Share Price Year-To-Date (YTD) return on June 20, 2025: 15.54%

Lonza Group AG Share Price Year-To-Date (YTD) return is 15.54% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Lonza Group AG 52-week low Share Price is USD 725.28 on June 20, 2025, which is 5.95% above the current Share Price.
Lonza Group AG 52-week low Share Price is USD 537.88 on June 20, 2025, which is -21.43% below the current Share Price.
Lonza Group AG average Share Price for the last 52 weeks is USD 632.44.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

Swiss Stock Exchange: LONN.SW

Lonza Group AG

CEO	Dr. Wolfgang Wienand Ph.D.
IPO Date	Nov. 1, 1999
Location	Switzerland
Headquarters	Muenchensteinerstrasse 38
Employees	17,995
Sector	🏥 Health Care
Industries Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.